DRMA vs RLMD

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 23, 2026

DRMA

36.9
AI Score
VS
RLMD Wins

RLMD

48.0
AI Score

Investment Advisor Scores

DRMA

37score
Recommendation
SELL

RLMD

48score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric DRMA RLMD Winner
Net Income -4.81M -45,015 RLMD
Operating Income -4.94M -45,015 RLMD
ROE -138.0% 329.6% RLMD
ROA -90.5% -225.0% DRMA
Total Assets 5.32M 20,009 DRMA
Cash 4.41M 15,290 DRMA
Current Ratio 3.40 0.55 DRMA
Free Cash Flow -5.01M -10,059 RLMD

Relative Price Performance (Last 90 Days)

DRMA 1M: +12.7% · 3M: +14.5% RLMD 1M: -11.0% · 3M: -35.8%

Current Technical Phase

DRMA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (0.7% over 20 days), RSI 57

RSI (14): 57.1 · Price: $1.42

RLMD

Markdown
Sell / avoid

Price below a falling SMA50 (slope -11.2%), weak momentum, RSI 35

RSI (14): 34.6 · Price: $4.63

Fundamentals Snapshot

Metric DRMA RLMD
Market Cap
Forward P/E -1.0 -8.3
Trailing P/E
Revenue (TTM)
Revenue Growth 0.0% 0.0%
Gross Margin
Operating Margin 0.0% 0.0%
EPS -4.20 -0.91
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, RLMD is currently the stronger investment candidate, winning 4 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.